CRISPR Therapy Leaves the Trial Setting: Louisiana Sickle Cell Patient Achieves Functional Cure

For many patients with sickle cell disease, "cure" has long not been an easy word to fit into everyday plans. Pain crises, hospitalization, organ damage, and career limitations often arrive in life sooner than medical advances do. Now, a young patient in Louisiana has completed a CRISPR gene-editing treatment course and been described by his medical team as having achieved a functional cure, giving this approved cutting-edge therapy its first concrete case in the southern U.S. Gulf region.

Manning Family Children’s Hospital said that 23-year-old Daniel Cressy rang the bell marking a treatment milestone inside the New Orleans hospital on June 22, becoming the first sickle cell patient in Louisiana and the Gulf South region to receive Casgevy CRISPR/Cas9 gene-editing therapy and achieve a functional cure. A follow-up report the same day by the U.K.’s The Guardian also confirmed that Cressy is from Metairie, Louisiana, and that the treatment was provided by Manning Family Children’s Hospital.

This therapy does not rewrite genes directly inside the body. Instead, a patient’s own hematopoietic stem cells are first removed, genetically edited outside the body, and then infused back into the patient. According to the hospital, Casgevy aims to increase production of fetal hemoglobin, thereby reducing the deformation of red blood cells into a sickle shape and lowering the risk of blocked blood vessels and severe pain crises. Cressy’s cells were reportedly collected in late 2025 and sent to Scotland for genetic modification, then returned to New Orleans in March 2026; he subsequently underwent chemotherapy to clear his existing diseased blood-forming system and received the edited cells on March 18.

This process also illustrates why "functional cure" remains a term that needs to be understood precisely. It usually means that a patient no longer experiences the core symptoms of the disease or has a sharply reduced dependence on supportive care such as transfusions and emergency visits, but it does not mean there are no subsequent risks. Cressy was discharged after recovering in the hospital for about one month, and the hospital said his hemoglobin level had reached the highest point of his life. However, the public information still comes mainly from the hospital and media reports, and long-term follow-up data, complete laboratory indicators, or additional case results from the same center have not yet been provided.

Background Context

Sickle cell disease is an inherited blood disorder that mainly affects people of African descent and can cause chronic pain, repeated hospitalization, and shortened life expectancy. Manning Family Children’s Hospital noted that Louisiana has a high number of sickle cell cases relative to its population in the United States, giving local capacity to establish accessible gene and cell therapy significance beyond a single case. For Cressy, the treatment also involves another layer of reality: he hopes to pursue a career as a commercial pilot, and the disease had made it difficult for him to pass the related medical requirements.

However, the real test for therapies such as Casgevy has only just begun to move from approval into everyday medical care. Cell collection, international manufacturing, chemotherapy conditioning, prolonged inpatient monitoring, and follow-up all make treatment highly dependent on hospital infrastructure, insurance payment, and the patient’s physical condition. Cressy’s case therefore brings a restrained optimism: gene editing has indeed begun to change the life paths of some patients, but making this path an option that more people can reach will still require time, data, and the capacity of the medical system to keep pace.